v3.19.3.a.u2
Quarterly Financial Data (unaudited) (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 12 Months Ended
Nov. 01, 2019
Sep. 06, 2019
Jun. 20, 2019
Feb. 21, 2019
Nov. 02, 2018
Sep. 07, 2018
Jun. 14, 2018
Feb. 15, 2018
Oct. 27, 2017
Sep. 08, 2017
Jun. 22, 2017
Feb. 16, 2017
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Quarterly Financial Data                                              
Net revenues                         $ 8,704 $ 8,479 $ 8,255 $ 7,828 $ 8,305 $ 8,236 $ 8,278 $ 7,934 $ 33,266 $ 32,753 $ 28,216
Gross margin                         6,698 6,559 6,436 6,134 6,283 6,401 6,344 6,007      
Net earnings                         $ 2,801 [1] $ 1,884 [2] $ 741 [3] $ 2,456 [4] $ (1,826) [1] $ 2,747 [2] $ 1,983 [3] $ 2,783 [4] $ 7,882 $ 5,687 $ 5,309
Basic earnings per share (in dollars per share)                         $ 1.88 $ 1.27 $ 0.49 $ 1.65 $ (1.23) $ 1.81 $ 1.26 $ 1.74 $ 5.30 $ 3.67 $ 3.31
Diluted earnings per share (in dollars per share)                         1.88 1.26 0.49 1.65 (1.23) 1.81 1.26 1.74 5.28 3.66 3.30
Cash dividends declared per common share (in dollars per share) $ 1.18 $ 1.07 $ 1.07 $ 1.07 $ 1.07 $ 0.96 $ 0.96 $ 0.96 $ 0.71 $ 0.64 $ 0.64 $ 0.64 $ 1.18 $ 1.07 $ 1.07 $ 1.07 $ 1.07 $ 0.96 $ 0.96 $ 0.96 $ 4.39 $ 3.95 $ 2.63
After-tax cost (benefit) related to change in fair value of contingent consideration liabilities                         $ 438 $ 182 $ 2,300 $ 171 $ (375) $ 95 $ 485 $ (148) $ 3,091 $ 49 $ 626
After-tax restructuring charges                               $ 133              
After-tax charge to increase litigation reserves                                   $ 176   $ 100      
After-tax intangible asset impairment charge                           $ 912     $ 4,500            
After-tax income from legal settlements                         435                    
Calico Life Sciences LLC | Collaborative arrangement                                              
Quarterly Financial Data                                              
After-tax charge as a result of a collaboration agreement extension with Calico                                     $ 500        
Reata Pharmaceuticals Inc                                              
Quarterly Financial Data                                              
After-tax consideration from counterparty for reacquired rights                         $ 297                    
[1]
Fourth quarter results in 2019 included an after-tax charge of $438 million related to the change in fair value of contingent consideration liabilities offset by after-tax income of $435 million from a legal settlement related to an intellectual property dispute with a third party and $297 million from an amended and restated license agreement between AbbVie and Reata. Fourth quarter results in 2018 included an after-tax intangible asset impairment charge of $4.5 billion partially offset by an after-tax benefit of $375 million related to the change in fair value of contingent consideration liabilities.
[2]
Third quarter results in 2019 included after-tax charges of $912 million related to intangible asset impairment and $182 million related to the change in fair value of contingent consideration liabilities. Third quarter results in 2018 included after-tax litigation reserves charges of $176 million and $95 million related to the change in fair value of contingent consideration liabilities.
[3]
Second quarter results in 2019 included an after-tax charge of $2.3 billion related to the change in fair value of contingent consideration liabilities resulting from the April 2019 regulatory approvals of SKYRIZI for the treatment of moderate to severe plaque psoriasis. Second quarter results in 2018 included after-tax charges of $500 million as a result of a collaboration agreement extension with Calico and $485 million related to the change in fair value of contingent consideration liabilities.
[4]
First quarter results in 2019 included after-tax charges of $171 million related to the change in fair value of contingent consideration liabilities and restructuring charges of $133 million. First quarter results in 2018 included an after-tax benefit of $148 million related to the change in fair value of contingent consideration liabilities partially offset by after-tax litigation reserves charges of $100 million.